GS Krishnan, formerly regional president & MD, Novozymes South Asia Pvt Ltd, a Danish biotech company, has taken charge as the new Presiden...

The pandemic has reshaped the startup landscape. Stress took its toll but SaaS sector grasped at new opportunities and biotech firms rose t...

A clinical trial of drugs today is often based on Bayesian statistics. However, Bayesian logic is often forgotten by policymakers, resultin...

The latest capital raise will allow the company to complete its phase-1 studies for its GYROX series intravenous drug candidate, as well as...

"It is important to keep in mind that the best way to avoid challenges is not to get started at all," says Vijayaraghavan.

“We’re creating a bullet against organisms that are taking out humanity. Wouldn’t it be nice to get a battleground to test it on that’s rea...

Industry observers think that a big Indian investor may remain elusive. “We have the talent and technology,” says RA Mashelkar, National Re...

The microscope which set the world of biology on fire required expertise to operate. Without Ragunath, the microscope would be just like a ...

"At a time where the business narrative is predominantly dominated by tech, it is so heartening to see the Economics Times giving a platfor...

"If you can prevent the spread from one region of the hospital to another, you would reduce the rate in which people pick up infection in t...

Despite the complexities, long durations and dearth of money required for such research, several young companies are making a global impact...

A flagship government-funding programme has provided a springboard to India's biotechnology industry by backing innovative and risky projec...

Considering the state of the industry, and the presence of so many academic institutions in Bengaluru, seasoned entrepreneurs think that th...

This bio-cluster is situated not too far from the Indian Institute of Science (IISc), research-led university that is also generating start...

A life sciences or medical product company is yet to make it big anywhere in India, despite a startup culture that is 15 years old.

Being a scientist, Jayant Halder has just three kinds of weapons: a new drug, a method to tweak old drugs, and a paint that can slow down t...

Across geographies, big pharmaceutical companies seem to have stepped back from research and development (R&D) for new drug discovery in th...